skip to Main Content

PARP Inhibitors Make Inroads in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
In an interim analysis, 19 evaluable patients treated with Rubraca following platinum chemotherapy had a median progression-free survival (PFS) of 9.1 months and an overall response rate (ORR) of 37%. The data presentation was on 2 April.

The extension of PFS is a welcomed outcome for a disease defined by aggressive growth and high resistance to treatment. Along with positive results from AstraZeneca and Merck & Co’s Lynparza (olaparib) earlier this year, the AACR data suggest that PARP inhibitors are positioned to play a transformative role in the treatment of a subset of pancreatic cancer patients. Read more . . .

Back To Top